A Method for Predicting Therapeutic Response in Parkinson’s Disease


Executive Summary


MSU and Vanderbilt researchers have found a method for predicting therapeutic response in Parkinson’s disease. The leading treatments, levodopa and deep brain stimulation, are generally effective in treating the motor symptoms of Parkinson’s disease, but the clinical response is highly variable depending on the disease’s genotype. This technology allows doctors to customize medical treatments for Parkinson’s patients, increasing the therapy’s effectiveness for the individual patient.


Description of Technology


Our technology shows that Parkinson’s disease subjects possessing a single nucleotide polymorphism respond differently to optimized drug therapy and deep brain stimulation. As such, we propose that genotyping for this mutation in Parkinson’s disease could serve to inform therapeutic decisions regarding pharmacological vs. surgical management of Parkinson’s disease.


Key Benefits

  • Improved treatment- Serves to inform the best therapeutic decision in treating Parkinson’s disease specific to the patient
  • Customized medicine—genotyping



  • Personalized medicine for Parkinson’s Disease


Patent Status: 


Patent application published no. 20160319355


Licensing Rights Available


Full licensing rights available


Inventors: Caryl E. Sortwell, Ph.D. Jack W. Lipton, Ph.D. David Charles, M.D. Mallory Hacker, Ph.D.


Tech ID: TEC2015-0077


Alternative contact due to temporary leave:


Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829. 


Patent Information:


For Information, Contact:

Anupam Jhingran
Technology Manager
Michigan State University